BridgeBio Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BridgeBio Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q3 2024.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $27.1M, a 0.36% decline year-over-year.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $115M, a 14% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $115M, a 22.6% increase from 2022.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $93.8M, a 11.1% decline from 2021.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $106M, a 80.6% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $115M $27.1M -$99K -0.36% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $115M $21.5M -$5.73M -21.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $120M $28.9M +$5.37M +22.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $115M $37.1M +$14.5M +64.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $100M $27.2M +$8.57M +45.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $91.9M $27.2M -$1.13M -3.99% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $93M $23.5M -$804K -3.31% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $93.8M $22.6M +$71K +0.32% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $93.8M $18.7M +$2.53M +15.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $91.2M $28.3M -$3.73M -11.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $95M $24.3M -$10.6M -30.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $106M $22.5M +$10.4M +85.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $95.2M $16.1M -$1.57M -8.87% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $96.8M $32M +$13.6M +74.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $83.1M $34.9M +$24.7M +241% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $58.5M $12.1M +$2.14M +21.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $56.3M $17.7M +$11.9M +206% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $44.4M $18.4M +$15M +448% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $29.4M $10.2M +$7.99M +358% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $21.4M $10M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 $5.78M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $3.36M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $2.23M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.